AscellaHealth Establishes International Strategic Advisory Council, Enhances Global Life Sciences Support Services Amid Regulatory and Market Complexity
GRÄFELFING, Germany, June 9, 2026 /PRNewswire/ -- VERTANICAL today announced that Exilby® (VER-01) has received marketing authorization in Germany for the treatment of chronic...
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Generic Drug Market size & share revenue was valued at approximately USD 491.35 Billion in 2024 and is expected to reach USD 519.11 Billion in 2025 and is expected to reach around USD 926.54 Billion by 2034, at a CAGR of 6.55% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Alkem Laboratories Limited, Teva Pharmaceutical Industries Limited, Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Mylan N.V., Lupin Limited, STADA Arzneimittel AG, Hikma Pharmaceuticals plc, Torrent Pharmaceuticals Ltd., Endo International plc, Aurobindo Pharma Limited, Sawai Pharmaceutical Co. Ltd., Mallinckrodt plc, Amneal Pharmaceuticals Inc and others.
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Generic Drug Market size & share revenue was valued at approximately USD 491.35 Billion in 2024 and is expected to reach USD 519.11 Billion in 2025 and is expected to reach around USD 926.54 Billion by 2034, at a CAGR of 6.55% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Alkem Laboratories Limited, Teva Pharmaceutical Industries Limited, Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Mylan N.V., Lupin Limited, STADA Arzneimittel AG, Hikma Pharmaceuticals plc, Torrent Pharmaceuticals Ltd., Endo International plc, Aurobindo Pharma Limited, Sawai Pharmaceutical Co. Ltd., Mallinckrodt plc, Amneal Pharmaceuticals Inc and others.
/Not for distribution to U.S. news wire services or dissemination in the United States./TORONTO, June 8, 2026 /CNW/ - Apotex Health Corp. ("Apotex" or the...
SHANGHAI, June 9, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing,...
NEW YORK, June 8, 2026 /PRNewswire/ -- A coalition of leading U.S. pharmacy organizations, in collaboration with the National Kidney Foundation (NKF), is urging...
Enhanced Polar Compound Retention and SeparationTORRANCE, Calif., June 8, 2026 /PRNewswire/ -- Phenomenex Inc., a Danaher Company and a global leader in the research...
Enhanced Polar Compound Retention and SeparationTORRANCE, Calif., June 8, 2026 /PRNewswire/ -- Phenomenex Inc., a Danaher Company and a global leader in the research...
Enhanced Polar Compound Retention and SeparationTORRANCE, Calif., June 8, 2026 /CNW/ -- Phenomenex Inc., a Danaher Company and a global leader in the research...
(UPM, Helsinki, June 8, 2026 at 14:00 EEST) HELSINKI, June 8, 2026 /PRNewswire/ -- UPM is simplifying adhesive selection with purpose-built solutions designed for demanding...
REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) lyophilized vial for intravenous administration.
SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- Dong Bang Co Ltd is strengthening its position in the global veterinary pharmaceutical market with high-value...
SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of...